Blog

EyePoint Pharmaceuticals, Inc. – EYPT

EyePoint Pharmaceuticals, Inc. – EYPT

EyePoint Pharmaceuticals, Inc. is a small cap company that is in the business of developing eye products via a ‘long-term, sustained release delivery’ platform. Their current products that have been developed, tested, and are ready for the market is DEXYCU and YUTIQ. Although not yet approved by the FDA, Yutiq I suspect will get the green…

Read More Read More

3rd Quarter 2018 – Portfolio Update

3rd Quarter 2018 – Portfolio Update

The year has been pretty positive so far with the markets and economy showing impressive gains. Hope you as well are being rewarded with gains. Below are my updates on my picks for the third quarter.   TRXC – TransEnterix is still showing signs of decent growth. The new addition of a commercial officer should…

Read More Read More

SIFY – Closing Position

SIFY – Closing Position

After review of this telecom company, which has already exceeded my target of 100% share price growth, I’ve decided to go ahead and take profits. Hovering around the $2 mark is what I foresee happening in the share price for the next few months. Sify Technologies Inc. seems to be experiencing growth in its’ Indian…

Read More Read More

Portfolio Update – XXII and PRPO

Portfolio Update – XXII and PRPO

As is customary with any semi-active trader, periodic review of the companies in your portfolio is both critically and obviously important to maintain meaningful growth. In other words, I think of each portfolio dollar as an employee of my company. As manager, you want to move employees into areas where they each will continue to…

Read More Read More

Precipio, Inc. – PRPO

Precipio, Inc. – PRPO

I’ve been watching the ebb and flow of the market, keeping an eye out for potential accelerated growth candidates and have identified a possible gem. This pick is Precipio, Inc. (PRPO). This small cap company is in the business of providing cancer diagnostic products and services to the oncology market. Precipio is expanding the potential…

Read More Read More

Verastem, Inc – VSTM

Verastem, Inc – VSTM

We’re one month down into 2018 and I’ve come across another small cap with some pretty decent potential. If you haven’t noticed from looking at my other picks, biotech’s are a featured favorite sector of mine. So, let’s dive and discuss this next biotech pick, Verastem, Inc. and why it can be a lower risk,…

Read More Read More

3rd Quarter 2017 – Growth Portfolio Update

3rd Quarter 2017 – Growth Portfolio Update

AXN – As mentioned in the recent Aoxing Pharmaceutical blog, I ended my position in this stock as the company announced a delisting of their common stock. The remaining proceeds have been reinvested into 22nd Century Group and TransEnterix Inc. OBCI – Continuing to hold steady in this growth stock as it tracks towards $6.…

Read More Read More

Aoxing Pharmaceutical Company – AXN

Aoxing Pharmaceutical Company – AXN

The end of the road has been reached for this company! And I have to say, it will not be missed. Today, AXN has announced a deregistration of their common stock and eventual delisting. The main reason for this action gravitating towards the company’s financial woes. So, what are some takeaways? A lack of communication…

Read More Read More

22nd Century Group – XXII (update)

22nd Century Group – XXII (update)

The FDA Center for Tobacco Products just did WHAT last week?!! If you haven’t heard by now, a low nicotine tobacco/cigarette policy initiative is being enacted by the FDA. The purpose, lowering nicotine in cigarettes to non-addictive levels which is the same purpose of XXII. Here’s a link. I wouldn’t be surprised if the “non-addictive”…

Read More Read More

EnSync, Inc. – ESNC (Watchlist?)

EnSync, Inc. – ESNC (Watchlist?)

The prospect of solar power, a renewable resource for the next 4 or 5 billion years as long as there are humans left to use it, is an industry that is projected to triple in size over the next few years. This is according to the SEIA or Solar Energy Industries Association. This anticipated growth…

Read More Read More